Details

Pomen socialnega kapitala v oblikovanju izobraževalno-edukativnega procesa : diplomsko delo
ID Stamejčič, Ana (Author), ID Židan, Alojzija (Mentor) More about this mentor... This link opens in a new window

URLURL - Presentation file, Visit http://dk.fdv.uni-lj.si/diplomska_dela_1/pdfs/mb11_stamejcic-ana.pdf This link opens in a new window

Language:Slovenian
Work type:Bachelor thesis/paper
Typology:2.11 - Undergraduate Thesis
Organization:FDV - Faculty of Social Sciences
Place of publishing:Ljubljana
Publisher:[A. Stamejčič]
Year:2012
Number of pages:51 str.
PID:20.500.12556/RUL-20202 This link opens in a new window
UDC:37:316(043.2)
COBISS.SI-ID:31454813 This link opens in a new window
Publication date in RUL:11.07.2014
Views:1519
Downloads:164
Metadata:XML DC-XML DC-RDF
:
STAMEJČIČ, Ana, 2012, Pomen socialnega kapitala v oblikovanju izobraževalno-edukativnega procesa : diplomsko delo [online]. Bachelor’s thesis. Ljubljana : A. Stamejčič. [Accessed 27 April 2025]. Retrieved from: http://dk.fdv.uni-lj.si/diplomska_dela_1/pdfs/mb11_stamejcic-ana.pdf
Copy citation
Share:Bookmark and Share

Similar documents

Similar works from RUL:
  1. Pomen tumorskih matičnih celic in epitelno-mezenhimskega prehoda pri napredovanju nedrobnoceličnega raka pljuč
  2. Gene expression levels of the prolyl hydroxylase domain proteins PHD1 and PHD2 but not PHD3 are decreased in primary tumours and correlate with poor prognosis of patients with surgically resected non-small-cell lung cancer
  3. Proučevanje izražanja gena za fosfatidiletanolamin-N-metiltransferazo v nedrobnoceličnem pljučnem rakavem tkivu
  4. Uporabnost imunohistokemičnega določanja mutacij receptorja za epidermalni rastni faktor pri raku pljuč
  5. Sladkorna bolezen in športna vadba
Similar works from other Slovenian collections:
  1. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small cell lung cancer
  2. Outsourcing predictive biomarker testing in non-small cell carcinoma
  3. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
  4. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
  5. NSCLC molecular testing in Central and Eastern European countries

Back